Logo image of CAMP

CAMP4 THERAPEUTICS CORP (CAMP) Stock Fundamental Analysis

NASDAQ:CAMP - Nasdaq - US13463J1016 - Common Stock - Currency: USD

2  0 (-0.25%)

After market: 1.9713 -0.03 (-1.43%)

Fundamental Rating

1

CAMP gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 562 industry peers in the Biotechnology industry. CAMP has a bad profitability rating. Also its financial health evaluation is rather negative. CAMP has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CAMP has reported negative net income.
In the past year CAMP has reported a negative cash flow from operations.
In the past 5 years CAMP always reported negative net income.
In multiple years CAMP reported negative operating cash flow during the last 5 years.
CAMP Yearly Net Income VS EBIT VS OCF VS FCFCAMP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M

1.2 Ratios

CAMP's Return On Assets of -100.00% is in line compared to the rest of the industry. CAMP outperforms 59.18% of its industry peers.
Industry RankSector Rank
ROA -100%
ROE -121.15%
ROIC N/A
ROA(3y)-54.3%
ROA(5y)-38.38%
ROE(3y)-82.87%
ROE(5y)-73.07%
ROIC(3y)N/A
ROIC(5y)N/A
CAMP Yearly ROA, ROE, ROICCAMP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100

1.3 Margins

CAMP does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CAMP Yearly Profit, Operating, Gross MarginsCAMP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10K -10K 20K 30K

More info and screens

3

2. Health

2.1 Basic Checks

CAMP does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CAMP remains at a similar level compared to 1 year ago.
The number of shares outstanding for CAMP has been increased compared to 5 years ago.
The debt/assets ratio for CAMP has been reduced compared to a year ago.
CAMP Yearly Shares OutstandingCAMP Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
CAMP Yearly Total Debt VS Total AssetsCAMP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

CAMP has an Altman-Z score of -5.40. This is a bad value and indicates that CAMP is not financially healthy and even has some risk of bankruptcy.
CAMP has a Altman-Z score of -5.40. This is in the better half of the industry: CAMP outperforms 64.17% of its industry peers.
CAMP has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -5.4
ROIC/WACCN/A
WACC10%
CAMP Yearly LT Debt VS Equity VS FCFCAMP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

A Current Ratio of 8.07 indicates that CAMP has no problem at all paying its short term obligations.
The Current ratio of CAMP (8.07) is worse than 80.21% of its industry peers.
A Quick Ratio of 8.07 indicates that CAMP has no problem at all paying its short term obligations.
CAMP has a worse Quick ratio (8.07) than 83.60% of its industry peers.
Industry RankSector Rank
Current Ratio 8.07
Quick Ratio 8.07
CAMP Yearly Current Assets VS Current LiabilitesCAMP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for CAMP have decreased strongly by -1852.83% in the last year.
CAMP shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -99.32%.
The Revenue for CAMP have been decreasing by -70.90% on average. This is quite bad
EPS 1Y (TTM)-1852.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-369.57%
Revenue 1Y (TTM)-99.32%
Revenue growth 3Y-87.18%
Revenue growth 5Y-70.9%
Sales Q2Q%-98.79%

3.2 Future

Based on estimates for the next years, CAMP will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.46% on average per year.
Based on estimates for the next years, CAMP will show a very negative growth in Revenue. The Revenue will decrease by -25.99% on average per year.
EPS Next Y51.57%
EPS Next 2Y25.11%
EPS Next 3Y15.46%
EPS Next 5YN/A
Revenue Next Year498.28%
Revenue Next 2Y-16.95%
Revenue Next 3Y-25.99%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CAMP Yearly Revenue VS EstimatesCAMP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 100M 200M 300M
CAMP Yearly EPS VS EstimatesCAMP Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 5 -5 10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CAMP. In the last year negative earnings were reported.
Also next year CAMP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CAMP Price Earnings VS Forward Price EarningsCAMP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CAMP Per share dataCAMP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -10 -20

4.3 Compensation for Growth

CAMP's earnings are expected to grow with 15.46% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.11%
EPS Next 3Y15.46%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CAMP!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CAMP4 THERAPEUTICS CORP

NASDAQ:CAMP (5/23/2025, 9:17:46 PM)

After market: 1.9713 -0.03 (-1.43%)

2

0 (-0.25%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13 2025-05-13/amc
Earnings (Next)N/A N/A
Inst Owners50.65%
Inst Owner Change-1.3%
Ins Owners3.6%
Ins Owner Change0%
Market Cap40.32M
Analysts86
Price Target19.38 (869%)
Short Float %3.29%
Short Ratio1.3
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-112.08%
Min EPS beat(2)-237.33%
Max EPS beat(2)13.17%
EPS beat(4)1
Avg EPS beat(4)-617.02%
Min EPS beat(4)-2111.25%
Max EPS beat(4)13.17%
EPS beat(8)3
Avg EPS beat(8)-293.71%
EPS beat(12)5
Avg EPS beat(12)-219.93%
EPS beat(16)8
Avg EPS beat(16)-263.18%
Revenue beat(2)2
Avg Revenue beat(2)1802.77%
Min Revenue beat(2)340.84%
Max Revenue beat(2)3264.71%
Revenue beat(4)2
Avg Revenue beat(4)872.89%
Min Revenue beat(4)-100%
Max Revenue beat(4)3264.71%
Revenue beat(8)4
Avg Revenue beat(8)435.88%
Revenue beat(12)4
Avg Revenue beat(12)288.21%
Revenue beat(16)4
Avg Revenue beat(16)213.13%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-124.21%
EPS NQ rev (3m)-124.21%
EPS NY rev (1m)-398.31%
EPS NY rev (3m)-398.31%
Revenue NQ rev (1m)-99.56%
Revenue NQ rev (3m)-99.56%
Revenue NY rev (1m)-99.63%
Revenue NY rev (3m)-99.63%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 26.7
P/FCF N/A
P/OCF N/A
P/B 0.78
P/tB 0.78
EV/EBITDA N/A
EPS(TTM)-27.87
EYN/A
EPS(NY)-2.7
Fwd EYN/A
FCF(TTM)-2.77
FCFYN/A
OCF(TTM)-2.83
OCFYN/A
SpS0.07
BVpS2.58
TBVpS2.58
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -100%
ROE -121.15%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-54.3%
ROA(5y)-38.38%
ROE(3y)-82.87%
ROE(5y)-73.07%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr -36.09%
Cap/Sales 81.99%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.07
Quick Ratio 8.07
Altman-Z -5.4
F-Score3
WACC10%
ROIC/WACCN/A
Cap/Depr(3y)41.56%
Cap/Depr(5y)49.13%
Cap/Sales(3y)88.82%
Cap/Sales(5y)55.41%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1852.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-369.57%
EPS Next Y51.57%
EPS Next 2Y25.11%
EPS Next 3Y15.46%
EPS Next 5YN/A
Revenue 1Y (TTM)-99.32%
Revenue growth 3Y-87.18%
Revenue growth 5Y-70.9%
Sales Q2Q%-98.79%
Revenue Next Year498.28%
Revenue Next 2Y-16.95%
Revenue Next 3Y-25.99%
Revenue Next 5YN/A
EBIT growth 1Y-172.75%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-42.89%
EBIT Next 3Y-23.55%
EBIT Next 5YN/A
FCF growth 1Y-65.62%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-187.31%
OCF growth 3YN/A
OCF growth 5YN/A